Medicare Rx "Non-Interference" Provision Is Bipartisan Target, Former CMS Official Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Statutory language prohibiting HHS from negotiating prices with drug manufacturers will likely be repealed in the next two years regardless of the presidential election's outcome, Patton Boggs partner Kathleen Means says.
You may also be interested in...
Democratic VP Nominee Edwards Bolsters Kerry’s “Affordable Health Care” Agenda
Sen. Edwards is an advocate of stricter DTC regulation, generic patent law reform, comparative effectiveness research and DoJ investigation of manufacturer “price gouging.”
Democratic VP Nominee Edwards Bolsters Kerry’s “Affordable Health Care” Agenda
Sen. Edwards is an advocate of stricter DTC regulation, generic patent law reform, comparative effectiveness research and DoJ investigation of manufacturer “price gouging.”
Medicare Rx "Non-Interference" Provision Protects Patients, PhRMA CEO Maintains
Language in the Medicare prescription drug law that prohibits HHS from "interfering" in drug price negotiations will ensure that patients have more therapeutic options, Pharmaceutical Research & Manufacturers of America CEO Alan Holmer maintained during the trade group's annual meeting in Palm Beach, Fla. April 2.